The US Patent and Trademark Office has invalidated Seagen's patent (No. 10,808,039), which covers ADC technologies including auristatin peptides linked with antibodies using a specific linker technology. This decision marks a critical point in Seagen’s ongoing legal dispute with Daiichi Sankyo.
